文献速递头颈外科

RECIST与PERCIST评估头颈鳞癌放化疗后颈部疗效

Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma.
PubMed 文献 · Head Neck · 2020-12-23

该回顾性研究纳入101例头颈鳞癌患者,比较RECIST、PERCIST及PET/CT定性评估对放化疗后颈部疗效的判定。PERCIST阳性预测值优于RECIST(47% vs. 36%),阴性预测值相当(78%);联合RECIST与PERCIST可提高阳性预测值至55%且不降低阴性预测值。HPV相关口咽癌中阴性预测值达100%,但阳性预测值较低(14%-33%)。

要点

  • PERCIST阳性预测值优于RECIST(47% vs. 36%),阴性预测值相当(78%)
  • 联合RECIST与PERCIST可提高阳性预测值至55%且不降低阴性预测值
  • HPV相关口咽癌中阴性预测值达100%,但阳性预测值仅14%-33%

核心结论

  • 联合RECIST与PERCIST可能优化放化疗后颈部管理决策。
  • HPV状态会影响疗效评估的准确性。

研究设计与样本

  • 回顾性研究,纳入101例头颈鳞癌患者。
  • 比较RECIST、PERCIST及PET/CT定性评估对放化疗后颈部疗效的判定。

主要发现

  • PERCIST阳性预测值优于RECIST(47% vs. 36%),阴性预测值相当(78%)。
  • 仅3/15例单一RECIST或PERCIST不完全缓解患者出现区域治疗失败。
  • 联合RECIST与PERCIST提高阳性预测值至55%且不降低阴性预测值,区域治疗失败风险比最高。
  • 联合RECIST与PET/CT定性评估也提高阳性预测值至50%。
  • HPV相关口咽癌中阴性预测值达100%,阳性预测值仅14%-33%。

关键数值与推荐

  • RECIST阳性预测值36%,阴性预测值78%。
  • PERCIST阳性预测值47%,阴性预测值78%。
  • 联合RECIST与PERCIST阳性预测值55%,阴性预测值未降低。
  • 联合RECIST与PET/CT定性评估阳性预测值50%。
  • HPV相关口咽癌中阴性预测值100%,阳性预测值14%-33%。

临床怎么用

  • 放化疗后颈部评估可考虑联合RECIST与PERCIST以优化决策。
  • HPV相关口咽癌需注意疗效评估阳性预测值较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An optimal approach to imaging assessment of neck after chemoradiotherapy must be established to avoid unnecessary neck dissection. METHODS: We retrospectively examined 101 patients and compared between Response evaluation criteria in solid tumors (RECIST), PET response criteria in solid tumors (PERCIST), and positron emission tomography/computed tomography (PET/CT) qualitative assessment. RESULTS: PERCIST was superior to RECIST in positive predictive value (PPV; 47% vs. 36%), with equivalent negative predictive value (NPV; 78%). Only 3 of 15 patients with incomplete responses on either RECIST or PERCIST alone had regional treatment failure, and the combination of RECIST and PERCIST improved PPV (55%) without reducing NPV. This combination yielded the highest hazard ratio of regional treatment failure. The combination of RECIST and PET/CT qualitative assessment also improved PPV (50%). In human papillomavirus (HPV)-related oropharyngeal cancer, NPV was 100% across the imaging assessments, while PPV was poor (14%-33%). CONCLUSIONS: Combining RECIST and PERCIST might optimize decision making in neck management after chemoradiotherapy. HPV status would affect the accuracy of response evaluation.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Kishikawa T, Suzuki M, Takemoto N, et al. Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST) for response evaluation of the neck after chemoradiotherapy in head and neck squamous cell carcinoma. Head Neck. 2020. PMID: 33368784. doi:10.1002/hed.26583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。